Dear All
The National Institute for Health and Care Excellence (NICE) are reviewing olaparib for non-BRCA women. The name of the appraisal is: Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy.
As part of the process we make a submission, and we can also nominate someone to be an expert patient to present their experience to the NICE committee. If you have any comments you'd like included in the submission, or if you'd like to be an expert patient at the committee meeting, please let me know. You can comment below or send me a private message.
It would be particularly helpful to hear from anyone who is non-BRCA and has been able to access olaparib through a trial or privately.
If you want to be an expert patient please let me know your email address as I will need to send you paperwork to fill out. Please don't leave your email in the comments below, please either private message me or email me at support@ovacome.org.uk. The committee meeting you will need to attend is on Thursday 16 August 2018 in London.
Best wishes
Anna
Ovacome Support Service Manager